Yüklüyor......
Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
Paricalcitol and cinacalcet have been recommended to reduce parathyroid hormone (PTH) levels for patients with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), and they are able to reduce the risk of hypercalcemia and hyperphosphatemia. However, to date, it has remained uncerta...
Kaydedildi:
| Yayımlandı: | Exp Ther Med |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444362/ https://ncbi.nlm.nih.gov/pubmed/32855693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2020.9044 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|